BioThrax + AV7909 Formulation 1 + AV7909 Formulation 2 + AV7909 Formulation 3 + AV7909 Formulation 4 + Control
Phase 1Completed 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Bacillus Anthracis (Anthrax) Infection
Conditions
Bacillus Anthracis (Anthrax) Infection
Trial Timeline
Dec 1, 2010 → Jun 1, 2012
NCT ID
NCT01263691About BioThrax + AV7909 Formulation 1 + AV7909 Formulation 2 + AV7909 Formulation 3 + AV7909 Formulation 4 + Control
BioThrax + AV7909 Formulation 1 + AV7909 Formulation 2 + AV7909 Formulation 3 + AV7909 Formulation 4 + Control is a phase 1 stage product being developed by Emergent BioSolutions for Bacillus Anthracis (Anthrax) Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT01263691. Target conditions include Bacillus Anthracis (Anthrax) Infection.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01263691 | Phase 1 | Completed |